Corona Updates

India to procure over 30 crore COVID-19 vaccine doses per month by January : Sources

India will have a vaccine capacity of 28 crore doses this month, which includes 22 crore Serum Institute of India’s Covishield and 6 crore doses of Bharat Biotech Biotech’s Covaxin and production of 60 lakh Zydus Cadila’s ZyCoV-D doses are also ready, said government sources. India will have a capacity of more than 30 crores by next year per month, which includes Covishield, Covaxin, ZyCoV-D and Biological E. New Delhi [India] : According to the sources, the production of 60 lakh doses of Zydus Cadila’s ZyCoV-D are already ready with the company and Biological E will be submitting the data till November end of phase -3 trials. The Biological E is the third Indian company to make Covid-19 vaccines. The company has also started stockpile doses.Biological E will be providing 30 crore doses and another company that is expected to provide doses is Gennova…

Corona Updates TOP NEWS UPDATES

Zydus Cadila to seek approval for two-dose regimen of its approved three-dose COVID-19 vaccine in India

Considering the burden on healthcare and the expense of buying three doses, Zydus Cadila is planning to seek approval for the two-dose regimen of its needle-free COVID-19 vaccine, ZyCoV-D, days after the vaccine was approved by India’s drugs regulator for emergency use in India on August 20. New Delhi [India], September 12 : The trials for the two-dose regimen are underway. 2mg of the vaccine has been prescribed in each dose of the present-day three-dose vaccine i.e. total of 6 mg. The company is now evaluating a 2 dose regime with 3mg in each dose.The vaccine is said to be pathbreaking as it is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use.A plasmid DNA vaccine uses non-replicating DNA molecules. As per Zydus Cadila, the vaccine which when administered produces the spike…

TOP NEWS UPDATES

Zydus Cadila seeks Emergency Use Authorisation for its Covid-19 vaccine ZyCoV-D in India

Zydus Cadila seeks Emergency Use Authorisation for its DNA vaccine, ZyCoV-D, for 12 years and above in India. Zydus Cadila has applied for Emergency Use Authorisation (EUA) nod from the Drugs Controller General of India (DCGI) for the launch of its DNA vaccine, ZyCoV-D, for 12 years and above. The company said that its vaccine has completed the third phase of trial. If DGCA grants approval, ZyCoV-D will join Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik V vaccines to be authorized for emergency use in India. According to the company’s claim, ZyCoV-D showed safety and efficacy during a late-stage trial . It involved more than 28,000 volunteers across the country. This included 1,000 subjects in the 12-18 year age group. Zydus said that the study was carried out during the peak of second wave in India. It said that the drug…